Valion Bio, Inc 8-K, filed Jan 26, 2024
Valion Bio, Inc. (VBIO)
About this 8-K
Valion Bio, Inc filed this 8-K on January 26, 2024, reporting on events of January 22, 2024.
Items reported
- Item 1.02: Ended a material agreement
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.02 Termination of a Material Definitive Agreement.
The information set forth in Item 5.02 of this Current Report regarding the Sabia Employment Agreement (as defined in Item 5.02, below) is incorporated by reference into this Item 1.02.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 22, 2024, Ryan Sabia was terminated as an employee and Chief Operating Officer of Tivic Health Systems, Inc. (the “Company”), effective immediately. As a result of his termination, his executive offer letter agreement dated April 1, 2022 (the “Sabia Employment Agreement”) also terminated on January 22, 2024.
Mr. Sabia’s termination was not related to the Company’s financial or operating results or to any disagreements or concerns regarding the Company’s financial or reporting practices. Mr. Sabia will not be entitled to any severance payment in connection with the termination of his employment. He will receive salary and benefits earned through January 22, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
TIVIC HEALTH SYSTEMS, INC. |
|
|
|
|
Date: |
January 26, 2024 |
By: |
/s/ Jennifer Ernst |
|
|
|
Name: Jennifer Ernst |